Lexicon Pharmaceuticals (NASDAQ:LXRX) issued its earnings results on Thursday. The biopharmaceutical company reported $2.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.31 by $0.80, Fidelity Earnings reports. The company had revenue of $294.45 million during the quarter, compared to analyst estimates of $12.00 million. The business’s revenue for the quarter was up 4124.5% compared to the same quarter last year. During the same quarter last year, the company posted ($0.26) EPS.
LXRX traded down $0.36 on Friday, hitting $3.52. 1,316,800 shares of the company’s stock were exchanged, compared to its average volume of 1,292,482. The firm has a market cap of $419.77 million, a PE ratio of -3.09 and a beta of 0.95. Lexicon Pharmaceuticals has a twelve month low of $1.13 and a twelve month high of $9.15. The stock has a fifty day moving average of $3.52 and a two-hundred day moving average of $4.21.
Several research firms recently weighed in on LXRX. Zacks Investment Research upgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 price objective on the stock in a research note on Saturday. Gabelli upgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a research note on Wednesday, September 11th. Wedbush reiterated a “buy” rating and set a $17.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Friday, October 4th. Stifel Nicolaus lowered shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $10.00 to $4.00 in a research note on Monday, July 29th. Finally, BidaskClub lowered shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company’s stock. Lexicon Pharmaceuticals has an average rating of “Hold” and a consensus target price of $6.45.
In other Lexicon Pharmaceuticals news, Director Christopher J. Sobecki bought 99,249 shares of Lexicon Pharmaceuticals stock in a transaction that occurred on Friday, September 13th. The stock was purchased at an average cost of $2.41 per share, for a total transaction of $239,190.09. Following the completion of the acquisition, the director now owns 13,645 shares of the company’s stock, valued at approximately $32,884.45. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Lonnel Coats bought 40,000 shares of Lexicon Pharmaceuticals stock in a transaction that occurred on Monday, August 19th. The shares were acquired at an average price of $1.35 per share, with a total value of $54,000.00. Following the completion of the acquisition, the insider now directly owns 87,695 shares of the company’s stock, valued at approximately $118,388.25. The disclosure for this purchase can be found here. Insiders have purchased 255,749 shares of company stock valued at $578,510 over the last 90 days. 6.40% of the stock is currently owned by insiders.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Featured Article: Lock-Up Period Expiration
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.